Omalizumab improves outcomes in chronic rhinosinusitis with nasal polyps
03 Jun 2020
byElaine Soliven
Treatment with omalizumab, an anti-IgE monoclonal antibody, significantly improves outcomes in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP), regardless of asthma status, based on a pooled analysis of the POLYP 1 and POLYP 2* studies presented at AAAAI 2020.